Micafungin Accordpharma (Micafungin)

Micafungin inhibits the fungal enzyme β‑1,3‑D‑glucan synthase, which is essential for synthesising β‑(1,3)‑D‑glucan, a critical component of the fungal cell wall. By disrupting cell‑wall formation, the drug causes osmotic instability and cell lysis, leading to selective fungal killing while sparing human cells.

The appropriate dose of Micafungin Accordpharma is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and the therapeutic setting. Dosage regimens are individualized and should follow the latest clinical guidelines and the product’s prescribing information.

Safety data for micafungin during pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including cold‑chain logistics if required) and any necessary import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, unlike azoles that inhibit ergosterol synthesis or polyenes that bind membrane sterols. Echinocandins generally have a favorable safety profile, limited drug‑drug interactions, and are effective against many Candida species, including those resistant to azoles. However, they are administered intravenously and may be less active against certain moulds.

Micafungin Accordpharma should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product must be transported, maintain the cold‑chain throughout to preserve stability and potency.

Micafungin Accordpharma is given as an intravenous infusion. The infusion is typically administered over 30‑60 minutes, depending on the clinical protocol and patient tolerance. Administration should be performed by qualified healthcare personnel in a setting equipped for intravenous therapy and monitoring for infusion‑related reactions.

Serious adverse events include severe hypersensitivity reactions such as anaphylaxis or angioedema, significant hepatotoxicity manifested by marked elevations in liver enzymes or jaundice, and hematologic abnormalities like neutropenia or thrombocytopenia. Prompt recognition and medical intervention are essential if any of these events occur.

Micafungin is contraindicated in patients with a known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for individuals with pre‑existing severe liver disease, uncontrolled renal impairment, or those receiving interacting medications that cannot be safely managed. Clinical judgment should guide use in pregnant or breastfeeding women.